Want to see GB:TRLS full AI Analyst Report?
Trellus Health PLC (TRLS) AI Stock Analysis
Trellus Health PLC
(LSE:TRLS)
The stock receives a neutral score of 50, reflecting a balance of risks and potential. Weak financial performance due to significant losses and cash burn is partially offset by a debt-free balance sheet and strong revenue growth. Technicals are mixed with some positive momentum but high volatility, while valuation remains unattractive given the lack of profitability. Trellus Health remains a speculative investment.
Trellus Health PLC (TRLS) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 62.72K
- Dividend Yield
- ―
- Average Volume (3M)
- 2.80M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 4.06
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 31
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Trellus Health PLC Business Overview & Revenue Model
Company Description
Trellus Health plc delivers digital health management services for long-term illnesses, primarily serving businesses and insurance companies. The cornerstone of their offerings is TrellusElevate, a secure, proprietary technology platform compliant wi...
How the Company Makes Money
null
Trellus Health PLC Financial Statement Overview
Summary
Trellus Health shows promising revenue growth (up 107% in 2024) and a debt-free balance sheet, but operating and net losses remain substantial, with negative cash flows and declining equity. The company is early-stage and not yet profitable, indicating high financial risk.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 359.00K | 114.00K | 19.00K | 18.00K | 25.00K | 0 |
| Gross Profit | 359.00K | 114.00K | 19.00K | 18.00K | 25.00K | 0 |
| EBITDA | -6.10M | -7.16M | -5.85M | -8.27M | -5.87M | -1.52M |
| Net Income | -6.89M | -7.78M | -6.34M | -8.81M | -5.90M | -1.52M |
Balance Sheet | ||||||
| Total Assets | 9.22M | 12.14M | 20.29M | 25.91M | 36.80M | 4.37M |
| Cash, Cash Equivalents and Short-Term Investments | 1.57M | 4.34M | 12.17M | 19.09M | 31.98M | 3.68M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 513.00K | 371.00K | 786.00K | 822.00K | 1.52M | 122.00K |
| Stockholders Equity | 8.71M | 11.77M | 19.50M | 25.09M | 35.27M | 4.25M |
Cash Flow | ||||||
| Free Cash Flow | -6.16M | -7.86M | -7.63M | -11.53M | -8.49M | -1.32M |
| Operating Cash Flow | -6.16M | -7.32M | -5.27M | -8.62M | -4.77M | -1.30M |
| Investing Cash Flow | -291.00K | -540.00K | -2.35M | -2.91M | -3.72M | -1.35M |
| Financing Cash Flow | 0 | 0 | 0 | 0 | 38.52M | 10.02M |
Trellus Health PLC Peers Comparison
Overall Rating
GB:KOO72Outperform
GB:IXI64Neutral- GB:TRLS50Neutral
GB:ABDX46Neutral
GB:COG44Neutral
GB:RENX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:KOO | 72Outperform | GBP 69.14M | 11.52 | 17.74% | ― | -6.51% | 108.62% |
| GB:IXI | 64Neutral | GBP 25.73M | -5.99 | -16.18% | ― | 13.04% | 15.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:TRLS | 50Neutral | GBP 172.05K | -0.03 | -49.78% | ― | ― | ― |
| GB:ABDX | 46Neutral | GBP 22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% |
| GB:COG | 44Neutral | GBP 15.11M | -9.30 | -54.17% | ― | 11.86% | 23.81% |
| GB:RENX | 40Underperform | GBP 36.54M | -3.44 | 675.00% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:TRLS | Trellus Health PLC | 0.04 | -0.51 | -92.73% | |
| GB:COG | Cambridge Cognition Holdings | 28.00 | -5.00 | -15.15% | |
| GB:IXI | IXICO plc | 11.75 | 0.25 | 2.17% | |
| GB:RENX | Renalytix Plc OTC | 5.45 | -1.93 | -26.15% | |
| GB:KOO | Kooth Plc | 190.00 | 58.00 | 43.94% | |
| GB:ABDX | Abingdon Health PLC | 9.00 | 2.75 | 44.00% |
Trellus Health PLC Corporate Events
Trellus Health Issues New Shares on Loan Note Conversion
NeutralTrellus Health plc has issued 16,438,845 new ordinary shares following the conversion of £50,000 in principal under the second tranche of its secured convertible loan notes. The issuance was slightly scaled back to offset previously over-allotte...
Trellus Health Issues New Shares on Loan Note Conversion, Updates Voting Rights
NeutralTrellus Health plc has issued 16,438,845 new ordinary shares following the conversion of £50,000 of principal from the second tranche of its secured convertible loan notes, with the issuance slightly reduced to offset an earlier over-allotment t...
Trellus Health Issues New Shares on Loan Note Conversion, Updates Voting Rights
NeutralTrellus Health has issued 16,454,134 new ordinary shares following the conversion of £50,000 of principal under the second tranche of its secured convertible loan notes. The new shares are expected to be admitted to trading on AIM around 5 March...
Trellus Health Completes Loan Note Conversion and Increases Share Capital
NeutralTrellus Health has converted approximately £65,000 of principal and accrued interest from its secured convertible loan notes into 16,804,593 new ordinary shares, completing the conversion of its first tranche notes. The new shares are expected t...
Trellus Health Wins J&J Contract Extension as TrialSet Deployments Scale Up
PositiveTrellus Health has secured a six-month extension to its contract with Johnson & Johnson Health Care Systems to mid-2026, maintaining existing economic terms to provide its Trellus Elevate platform to IBD patients prescribed J&J therapies. The...
Trellus Health Issues New Shares on Conversion of Loan Notes
NeutralTrellus Health plc has issued 5,637,205 new ordinary shares following the conversion of £21,000 of principal under its secured convertible loan notes, in line with shareholder approvals granted in January. The new shares are expected to be admit...
Trellus Health Issues New Shares on Loan Note Conversion
NeutralTrellus Health has issued 5,538,461 new ordinary shares following the conversion of £27,000 of principal under its secured convertible loan notes, a move that modestly expands its equity base. The new shares are expected to be admitted to tradin...
Trellus Health Deepens Pharma and CRO Ties as TrialSetâ„¢ Deployment Gathers Pace
PositiveTrellus Health reported ongoing operational progress across its key verticals, particularly in clinical trials, where it signed 12‑month contracts with global CROs ICON and PSI to deploy its Trellus TrialSet™ solution in Takeda- and Sanof...
Trellus Health Issues New Shares to Settle Loan Note Fees
NeutralTrellus Health plc has issued 19,230,769 new ordinary shares in lieu of cash payment for settlement fees related to its secured convertible loan notes, following shareholder approval at a recent general meeting. The new shares are expected to be admi...
Trellus Health Wins Overwhelming Shareholder Backing at General Meeting
PositiveTrellus Health plc announced that all resolutions put to shareholders at its General Meeting on 20 January 2026 were duly passed on a poll, with each motion receiving more than 99.8% of votes cast in favour. The strong shareholder support provides th...
Trellus Health Grants Share Options to Chairman to Align Incentives with Shareholders
PositiveTrellus Health has granted options over 807,541 ordinary shares to its chairman, Kevin Murphy, under the company’s existing share option plan at an exercise price of 0.525p, matching the pricing of a recent loan note arrangement with Mount Sina...
Trellus Health Seeks Up to £5m via Convertible Loan Notes to Extend Cash Runway
NegativeTrellus Health plans to raise up to £5 million via a 12‑month secured convertible loan note facility from an institutional investor, with warrants attached and funds available in staged tranches, subject to shareholder approval at a genera...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 22, 2026